Oncogenes in cell survival and cell death.
暂无分享,去创建一个
[1] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[2] Julian Downward,et al. RAS Interaction with PI3K: More Than Just Another Effector Pathway. , 2011, Genes & cancer.
[3] A. Fernández-Medarde,et al. Ras in cancer and developmental diseases. , 2011, Genes & cancer.
[4] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[5] C. Scott,et al. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. , 2010, Blood.
[6] P. Harari,et al. Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.
[7] T. Skorski,et al. Chronic myeloid leukemia: mechanisms of blastic transformation. , 2010, The Journal of clinical investigation.
[8] W. Weiss,et al. Myc proteins as therapeutic targets , 2010, Oncogene.
[9] K. Takeuchi,et al. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR‐targeting tyrosine kinase inhibitors , 2010, The FEBS journal.
[10] Kwok-Kin Wong,et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition , 2009, Proceedings of the National Academy of Sciences.
[11] J. Pelletier,et al. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. , 2009, Cancer research.
[12] D. Feldser,et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.
[13] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[14] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[15] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[16] H. Varmus,et al. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family , 2009, Oncogene.
[17] R. Johnstone,et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. , 2009, Blood.
[18] A. Strasser,et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis , 2009, Cell Death and Differentiation.
[19] B. Druker,et al. Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.
[20] L. Penn,et al. Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.
[21] C. Scott,et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas , 2008, Proceedings of the National Academy of Sciences.
[22] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[23] K. Shokat,et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. , 2008, The Journal of clinical investigation.
[24] B. Manning,et al. The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2 , 2008, Molecular and Cellular Biology.
[25] T. Skorski,et al. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress , 2008, Leukemia.
[26] T. McDonnell,et al. Cooperation of Ha‐ras and Bcl‐2 during multistep skin carcinogenesis , 2007, Molecular carcinogenesis.
[27] E. Schmidt,et al. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. , 2007, Cancer research.
[28] H. Stein,et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. , 2007, Blood.
[29] M. Henriksson,et al. The Myc oncoprotein as a therapeutic target for human cancer. , 2006, Seminars in cancer biology.
[30] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[31] F. Lozupone,et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.
[32] C. Grandori,et al. Activation by c-Myc of transcription by RNA polymerases I, II and III. , 2006, Biochemical Society symposium.
[33] E. Henske,et al. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease , 2005, Oncogene.
[34] M. Eilers,et al. Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.
[35] T. Skorski,et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. , 2004, Blood.
[36] S. Lowe,et al. Intrinsic tumour suppression , 2004, Nature.
[37] R. Sears. The Life Cycle of C-Myc: From Synthesis to Degradation , 2004, Cell cycle.
[38] S. Lowe,et al. Suppression of tumorigenesis by the p53 target PUMA. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[39] P. Bouillet,et al. Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[40] S. Lowe,et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.
[41] Yosef Yarden,et al. Signal transduction and oncogenesis by ErbB/HER receptors. , 2004, International journal of radiation oncology, biology, physics.
[42] S. Nicosia,et al. Akt Phosphorylation and Stabilization of X-linked Inhibitor of Apoptosis Protein (XIAP)* , 2004, Journal of Biological Chemistry.
[43] Channing J Der,et al. The dark side of Ras: regulation of apoptosis , 2003, Oncogene.
[44] Kenneth Chu,et al. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.
[45] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[46] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[47] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[48] G. Wahl,et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. , 2002, Molecular cell.
[49] S. Lowe,et al. Dissecting p53 tumor suppressor functions in vivo. , 2002, Cancer cell.
[50] J. Massagué,et al. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. , 2002, Nature.
[51] Riccardo Dalla-Favera,et al. Mechanisms of chromosomal translocations in B cell lymphomas , 2001, Oncogene.
[52] M. Eilers,et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. , 2001, Genes & development.
[53] B. Druker,et al. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. , 2000, The Lancet. Oncology.
[54] Tobias Schmelzle,et al. TOR, a Central Controller of Cell Growth , 2000, Cell.
[55] S R Datta,et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. , 2000, Molecular cell.
[56] J F Barrett,et al. Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[57] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[58] S. Lowe,et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.
[59] M. Roussel,et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.
[60] D. Felsher,et al. Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.
[61] L. Chin,et al. Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.
[62] S. Lowe,et al. INK 4 a / ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p 53 , 1999 .
[63] John Calvin Reed,et al. Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.
[64] K. Kinzler,et al. Landscaping the Cancer Terrain , 1998, Science.
[65] C. Y. Wang,et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. , 1997, Science.
[66] S. Lowe,et al. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.
[67] K. Kinzler,et al. Lessons from Hereditary Colorectal Cancer , 1996, Cell.
[68] H. Lovec,et al. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. , 1994, Oncogene.
[69] Gerard I. Evan,et al. Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.
[70] A. Strasser,et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.
[71] J. Hartley,et al. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. , 1977, Proceedings of the National Academy of Sciences of the United States of America.